



► PHARMA POOL

DR. UDIT BATRA

EMD MILLIPORE INTRODUCES CEO AND PRESIDENT



EMD Millipore, the life-sciences division of Merck KGaA, has appointed Udit Batra, Ph.D., as president and CEO, responsible for the organization's strategic direction to drive growth and product innovation as well as oversight of the worldwide operations. Dr. Batra is based at the company's U.S. headquarters in Massachusetts.

Dr. Batra comes to EMD Millipore from the consumer health division of Merck KGaA, where he successfully grew the business in established and emerging markets.

HUGH COLE

ARIAD NAMES CHIEF BUSINESS OFFICER



Ariad Pharmaceuticals has appointed Hugh Cole senior VP and chief business officer. Mr. Cole is responsible for global business and corporate development, licensing, and strategic planning.

Before joining Ariad, he spent seven years at Shire Pharmaceuticals, most recently as senior VP, strategic planning and program management, and as a global franchise head, and before that, as VP, business development.

DR. KAREN FERRANTE

TOKAI PHARMACEUTICALS APPOINTS HEAD OF R&D AND CHIEF MEDICAL OFFICER



Tokai Pharmaceuticals Inc. has appointed Karen Ferrante, M.D., head of R&D and chief medical officer. Dr. Ferrante, formerly oncology therapeutic area head for Takeda Pharmaceuticals and the Takeda Cambridge USA site head, brings almost 20 years of drug development experience and proven leadership in the pharmaceutical industry to Tokai.

KEN KELLER

DAIICHI SANKYO NAMES US LEAD



Ken Keller is joining Daiichi Sankyo Inc. as president of its commercial operations in the United States. In this role, Mr. Keller is responsible for leading marketing, sales, medical affairs, and supply chain operations for Daiichi Sankyo in the United States.

Most recently, Mr. Keller was executive VP and chief operating officer at Spectrum Pharmaceuticals, where he was responsible for global commercial,

medical, research and development, and manufacturing.

Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. With the appointment of Mr. Keller as the head of commercial operations at Daiichi Sankyo Inc., Dr. Glenn Gormley assumes the role of executive chairman and president, Daiichi Sankyo Inc., and retains his roles as president, Daiichi Sankyo Pharma Development, and as the global head of R&D for Daiichi Sankyo Co. Ltd.

Greg Barrett, who served as interim president for commercial operations, remains VP of marketing and managed markets at Daiichi Sankyo Inc.

► BIOTECHNOLOGY POOL

DR. MARC HEDRICK

CYTORI ANNOUNCES SENIOR MANAGEMENT CHANGES



Cytori Therapeutics has announced that Christopher Calhoun, CEO and director of Cytori Therapeutics, is retiring from the position of CEO of the company. Marc Hedrick, M.D., has been named to replace Mr. Calhoun as CEO, in addition to his current responsibilities as president and director.

Dr. Hedrick has served as president since 2004 and has overseen research, development, sales, and marketing groups.

DR. ADAM KOPPEL

BIOGEN IDEC NAMES SENIOR VP AND CHIEF STRATEGY OFFICER



Biogen Idec has appointed Adam Koppel, M.D., Ph.D., senior VP and chief strategy officer. Dr. Koppel is responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy. He reports to George Scangos, Ph.D., CEO, and is a member of the Biogen Idec management team.

Dr. Koppel joins Biogen Idec from Brookside Capital, the public equity affiliate of Bain Capital, where he served as a managing director since 2009.

► BIOPHARMA POOL

Dr. DAVID TIERNEY

ICON BIOSCIENCE NAMES PRESIDENT AND CEO

Icon Bioscience Inc., a specialty biopharmaceutical company focused on using its Verisome drug de-



livery platform to develop unique intraocular eye-care therapeutics, has named David Tierney, M.D., president and CEO.

Previously, Dr. Tierney served as president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in mid-2008.

► DIAGNOSTICS POOL

DR. MICHAEL PFALLER

T2 BIOSYSTEMS APPOINTS CHIEF MEDICAL OFFICER



T2 Biosystems, a company developing direct detection products designed to enable diagnostics, has named Michael Pfaller, M.D., as chief medical officer.

Dr. Pfaller is responsible for overseeing medical affairs, including infectious disease and hemostasis advisory boards, and clinical research, and physician education programs associated with the anticipated launch of the company's flagship diagnostic test, T2Candida, upon receipt of marketing authorization from the FDA.

Dr. Pfaller brings to T2 Biosystems more than 35 years of clinical and medical research experience and is currently Professor Emeritus at the University of Iowa Hospitals.

► SERVICE POOL

SHARON GREESON

CIS MAKES STRATEGIC ADDITION TO TEAM



Compliance Implementation Services (CIS) has named Sharon Greeson, strategic consultant, government pricing and programs.

Ms. Greeson, a Medicaid expert, supports the development of state communications and strengthens CIS' relationships with state directors of pharmacy benefits. She brings more than 25 years of experience in managing, designing, and implementing pharmacy programs, with expertise in program analysis, requirements evaluation, and solution development.

MICHAEL GRIFFITH

EXECUTIVE VP OF INVENTIV HEALTH APPOINTED



inVentiv Health, a life-science knowledge and services company, has appointed Michael Griffith executive VP. In this capacity, he heads inVentiv's

commercial and consulting businesses and reports to inVentiv Health CEO Paul Meister.

Most recently, Mr. Griffith was CEO of Laureate Biopharma, a contract manufacturing organization providing outsourced biologics development and manufacturing services.

VICKI KELEMEN

BLUEMOMENTUM ADDS LEADERSHIP TO WEST COAST TEAM



BlueMomentum, an Ashfield Healthcare Company, has named seasoned biopharma executive Vicki Kelemen as VP, collaboration specialist. Ms. Kelemen is charged with leading the company's business development on the West Coast. The appointment comes at a time when biopharma companies are realizing the benefits of putting patients at the center of their business strategies.

Before joining BlueMomentum, Ms. Kelemen held executive positions at Somaxon, Amylin, Maxim, Agouron (Pfizer), Dura, and Bayer Healthcare Pharmaceuticals.

BlueMomentum is changing the conversation among physicians, patients, and pharma from one of engagement to one of collaboration to bring better value to the brand and to the people.

CINDY KENT

3M DRUG DELIVERY SYSTEMS NAMES PRESIDENT AND GENERAL MANAGER



3M Drug Delivery Systems, which partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal, or microneedle drug delivery technology, has appointed Cindy Kent as its new president and general manager. She succeeds James Ingebrand, who was recently named president and general manager of 3M ESPE, 3M's dental division. Ms. Kent most recently served as the VP of strategy, business development and US medical key accounts for 3M Healthcare.

DR. ROSS MACLEAN

PRECISION HEALTH ECONOMICS NAMES CHIEF OPERATING OFFICER



Health economics and policy authority Precision Health Economics (PHE) has named Ross Maclean, M.D., Ph.D., as chief operating officer. Dr. Maclean's significant and varied background spans the provider, payer, and manufacturing worlds in multiple countries, encompassing leadership skills, management talents, and a rapid career progression.

Most recently, he spent 12 years of progressive responsibilities at Bristol-Myers Squibb, including leader of the U.S. Health Economics and Outcomes Research function.

AGENCY POOL

BORIS KUSHKULEY

INTOUCH SOLUTIONS EXPANDS MULTICHANNEL MARKETING EXPERTISE



Boris Kushkuley has joined Intouch Solutions, a marketing agency, as its executive VP, multichannel marketing and consulting. Mr. Kushkuley will join Intouch Solutions' New York office, where he is charged with leading development of effective multichannel marketing methodologies for major pharmaceutical clients. Before joining Intouch Solutions, he spent 11 years with Ogilvy CommonHealth Worldwide where he established and led its digital and multichannel practice. 



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0614-TalentPool



Searching for the right audience for your next e-mail campaign?

Target PharmaVOICE Readers with your E-mail Marketing Campaign

- Segment our opt-in e-mail database of 65,000+
- 20% off multiple emails
- 50% off all resends
- Best practices for better ROI
- Design and html coding available

Call 215-321-8656 or e-mail mwalsh@pharmavoices.com to discuss your next email promotion with Marah Walsh.

Pharma**VOICE**



▶ **BIOTECH POOL****DR. RANDOLPH JOHNSON****ATHERONOVA APPOINTS CHIEF OPERATING OFFICER**

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has named Randolph Johnson, Ph.D., chief operating officer.

Most recently, Dr. Johnson served as the chief of technology development and VP of research at KAI Pharmaceuticals, where he contributed to an equity exit and acquisition by Amgen in a \$315 million all-cash deal for the Velcalcetide (AMG-416) program, a novel peptide to treat patients with chronic kidney disease.

DR. BERNARD RAVINA**DR. DINAH SAH****VOYAGER THERAPEUTICS EXPANDS AND STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP**

Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), has named Bernard Ravina, M.D., VP, clinical development, and Dinah Sah, Ph.D., has been named a permanent member of the leadership team after serving as interim senior VP of neuroscience since the company's launch early this year.

Dr. Ravina is responsible for clinical development and strategy for Voyager's product programs. Before Voyager, Dr. Ravina was medical director in clinical development at Biogen Idec.

Dr. Sah is responsible for Voyager's discovery and preclinical development efforts and plays an instrumental role in key scientific decisions across the company. Before joining Voyager, Dr. Sah spent seven years at Alnylam Pharmaceuticals, where she was most recently VP of research, leading discovery research and multiple research and development programs.

Dr. MICHAEL TAYLOR**DECIPHERA PHARMACEUTICALS APPOINTS PRESIDENT AND CEO**

Deciphera Pharmaceuticals, a clinical stage biotechnology company developing improved kinase inhibitor treatments for cancer, has appointed Michael Taylor, Ph.D., as president and CEO. Dr. Taylor takes on the role of CEO at a time when Deciphera is making clinical progress with its kinase inhibitor product candidates for several types of cancers.

Before joining Deciphera, Dr. Taylor was CEO of Ensemble Therapeutics.

DR. RYUJI UENO**VLP THERAPEUTICS APPOINTS CHAIR AND CHIEF MEDICAL OFFICER**

VLP Therapeutics, a biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-VLP technology, has named Ryuji Ueno, M.D., Ph.D., chair and chief medical officer.

Previously, Dr. Ueno was co-founder and chair, CEO, and chief scientific officer, of Sucampo Pharmaceuticals.

▶ **BIOPHARMA POOL****DR. PANKAJ BHARGAVA****DICERNA PHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER**

Dicerna Pharmaceuticals, a developer of RNAi-based therapeutics, has appointed Pankaj Bhargava, M.D., as chief medical officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development and translational research gained in leading industry and academic institutions. In his role as chief medical officer, he is responsible for clinical development activities as well as regulatory affairs.

PAUL FIRUTA**NPS PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM**

NPS Pharmaceuticals, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, has named Paul Firuta president, U.S. commercial operations.

Most recently, Mr. Firuta was VP and general manager, Americas, for ViroPharma.

DR. DAVID RODMAN**MIRAGEN THERAPEUTICS EXPANDS EXECUTIVE LEADERSHIP TEAM**

miRagen Therapeutics, a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapeutics, has appointed David Rodman, M.D., executive VP of research and development. Dr. Rodman is an accomplished industry veteran who brings significant translational medicine and clinical development experience to the company's executive leadership team.

DR. JAMEY SKILLINGS**TOCAGEN NAMES CHIEF MEDICAL OFFICER**
Tocagen, a privately funded, clinical-stage biophar-

maceutical company pursuing the discovery, development, and commercialization of products that activate the immune system selectively against cancer (selective cancer immunotherapeutics), built on a novel gene therapy platform, has named Jamey Skillings, M.D., chief medical officer.

Dr. Skillings joins Tocagen from Pfizer, where she was most recently VP of global medical affairs for oncology.

▶ **EMERGING POOL****DR. ELLIOTT GOLDSTEIN****EUGENE WILLIAMS****IMMUNE CEO ANNOUNCES NEW OPERATIONAL LEADERSHIP TEAM**

Immune Pharmaceuticals has added two new senior members to its management team.

Elliott Goldstein, M.D., joins as chief medical officer. Dr. Goldstein brings a unique track record in the clinical, regulatory, and commercial development of new pharmaceuticals.

Eugene Williams joins as chief operating officer. Mr. Williams is a former senior VP at Genzyme, with senior roles integrating commercialization, drug development, and deal making.

ROBERT PRACHAR**TREVENA STRENGTHENS SENIOR LEADERSHIP**

Trevena, a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, has appointed Robert Prachar to the newly created position of senior VP, commercial and corporate strategy.

Mr. Prachar, who has served as a full-time consultant for the company since August 2013, brings more than 20 years of commercial leadership experience in the life-sciences industry.

DR. MAHENDRA RAO**Q THERAPEUTICS NAMES CHIEF STRATEGY OFFICER**

Q Therapeutics, an emerging biotechnology company developing innovative cell therapy products for the treatment of neurodegenerative diseases, has named Mahendra Rao, M.D., Ph.D., chief strategy officer and chairman of the scientific advisory board.

Dr. Rao is the scientific founder of Q and world renowned for his work with neural stem cells. Most recently, he served as director of the Intramural Center for Regenerative Medicine at the National Institutes of Health (NIH). **PV**

3RD ANNUAL

Annual Clinical Operations in Oncology Trials East Coast 2014



July 15th - 16th 2014, Boston, USA

“Spearheading clinical operation excellence and the development of strategic partnerships”

Following the success of previous years, the Clinical Operations in Oncology Trials East Coast conference is back and returns for its third annual event in Boston, USA on 15th – 16th July 2014.

Oncology trials make up over 30% of the U.S clinical trials highlighting the importance and lucrative nature of successful development of treatments. Despite this, there are a number of operational challenges facing the industry and limiting success.

This exclusively tailored event promises to deliver suggestions and solutions on how companies can differentiate themselves from competitors, optimise their oncology trials and achieve operational excellence.

The **3rd Annual Clinical Operations in Oncology Trials East Coast 2014** event prides itself on providing vast opportunities for extensive networking and allowing attendees to share best practice and develop solutions to critical challenges facing the industry as a whole through the use of speaker hosted roundtable sessions.

Key topics at this year's event include:

- Enhancing patient recruitment and retention in oncology trials
- Supporting the development of partnerships in oncology trials
- Improved operational strategies
- Global site selection, feasibility assessment, operations and site management
- Delving into key regulatory and review board guidelines

High calibre speakers include:

- **Fiona An**, Director, Global Oncology Development, **Pfizer**
- **Pablo Lapuerta**, Executive Vice President of Clinical Development and Chief Medical Officer, **Lexicon Pharmaceuticals**
- **Giovanni Abbadessa**, Vice President, Clinical Development, **ArQule**
- **Robert Arbeit**, Vice President, Clinical Development, **Idera Pharmaceuticals**
- **Heather DiBenedetto**, Head, Clinical Operations Group, **Novartis**
- **Howard Fingert**, Senior Medical Director, Clinical Intelligence, **Takeda**

Secure your place today by quoting reference code MK-SRPV
Free bookings for the two day conference for VP/Director/C level Executives!

Book now by visiting www.arena-international.com/oncologyusa